CGIM
BCRX icon

Cannon Global Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Cannon Global Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$253K Buy
+26,600
New +$207K 0.49% 62

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Cannon Global Investment Management's BCRX Position: Q1 2026 in Review

Cannon Global Investment Management opened a new position in BioCryst Pharmaceuticals (BCRX) in Q1 2026: 26,600 shares worth $253K. The stake represents 0.49% of the portfolio and ranks #62 among its holdings.

301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Cannon Global Investment Management held 26,600 shares of BioCryst Pharmaceuticals worth $253K as of Q1 2026.
  • BioCryst Pharmaceuticals was a new Cannon Global Investment Management position in Q1 2026.
  • BioCryst Pharmaceuticals made up 0.49% of Cannon Global Investment Management's portfolio in Q1 2026, its #62 holding.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Cannon Global Investment Management's 13F filing for Q1 2026, filed 21 Apr 2026.